Study ID: CTSU S1001
Title:

Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)

Description:

The purpose of this study is to give more intensive treatment to patients whose PET/CT shows that they have a greater chance of still having active lymphoma (PET/CT scan is positive after 3 cycles of therapy), and to give less intensive treatment to patients whose PET/CT scan shows that they have a smaller chance of still having active lymphoma (PET/CT scan is negative after 3 cycles of therapy). Participants in this study have limited (or early stage) Diffuse Large B Cell non-Hodgkin Lymphoma (DLBCL). Limited (or early) Stage Diffuse Large B-cell non-Hodgkin Lymphoma is curable in many people, but some still can relapse (the cancer comes back), and some develop side-effects during or after treatment. A radiologic test called PET/CT scan is used in this study to determine treatment after three (3) cycles of a standard lymphoma chemotherapy called R-CHOP (the drugs are Rituximab, Cyclophosphamide, vincristine, doxorubicin, and prednisone). The agents used in this study are FDA approved for lymphoma treatment.

Location:
Fargo Region, Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak MD,Preston Steen, MD
Disease:
NHL (Non-Hodgkins Lymphoma)
Stage:
Phase II

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list